Regeneron (REGN), Sanofi (SNY) Report Plans to Restructure Antibody Collaboration for Kevzara (sarilumab) and Praluent (alirocumab)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. SPY
5. ACN
6. IBM
7. META
8. PFE
9. TSLA
10. DPZ

Go back to Regeneron (REGN), Sanofi (SNY) Report Plans to Restructure Antibody Collaboration for Kevzara (sarilumab) and Praluent (alirocumab)

Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

December 10, 2019 8:29 AM EST

TARRYTOWN, N.Y. and PARIS, Dec. 10, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced their intent to simplify their antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab) by restructuring into a royalty-based agreement. Under the proposed restructuring, Sanofi is expected to gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent. Regeneron is expected to gain sole U.S. rights to Praluent.... More